Shares of Heron Therapeutics Inc. soared 37% in premarket trade Friday, after the company said late Thursday that a late-stage study of its treatment for chemotherapy-induced nausea and vomiting achieved its primary endpoint. The shares are on track to open at the highest level since Jan. 30, 2013. The company also said its SUSTOL product candidate was "well tolerated," with significantly more patients being satisfied with their therapy based on a quality-of-life questionnaire. Heron expects a resubmission of a new drug application for SUSTOL to the U.S. Food and Drug Administration in mid-2015. "Symptom management in patients receiving cancer treatment represents a significant unmet medical need, and the results of this study represent another step forward in this important clinical space," said Ian Schnadig, principal investigator, U.S. Oncology Research, Compass Oncology.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below